Innovative Solutions in Pre-Filled Syringes for Biologics and Ophthalmic Applications
July 11, 2024 – 4pm (CEST) / 10am (EDT)
How to face challenges of biologic market segment and reduce complexity with patient centric drug delivery devices
The pre-filled syringes market has grown rapidly in recent years as a result of converging factors: the vast biologics market, a growing number of biosimilar entrants, the ongoing rise of self-administration, and rising chronic illness due to ageing populations.
There is not a solution that fits all the challenges. For this reason, Pharma Companies need tailored syringes fit for each intended uses.
In this webinar, Enrico Barichello, Product Manager for Syringe Platform in Stevanato Group and Alan Xu, Product Manager for Analytical Services in Stevanato Group, will be discussing the best strategy between customers and suppliers to select the right container based on the key features of the combination product.
This webinar will address the following challenges:
1. Streamline the integration of the primary drug containers and delivery systems
Early-stage analytical services can facilitate the selection of the right drug containment solution (DCS) and drug delivery system (DDS) to assess complete compatibility. The benefits allow to select optimal DCS and DDS to speed up the decision-making process and time to market which is crucial for new products.
2. Tackling Biologics - complex, sensitive and hard-to-stabilize drugs
Plasma treatment on prefillable syringes ensures exceptional stability and resilience over-time. This advanced coating is the perfect match for a broad range of applications for Biologics including ophthalmology, monoclonal antibody and mRNA and viral vector products requiring cold-temperature storage.
3. Acceleration of therapy moving from hospital to home care, driving adoption of drug delivery systems
Accurate barrel dimensions & tolerances are crucial for device integration as they can impact functionality. In the webinar we will speak about how to assure compatibility with new generation and commercially available auto-injectors.
4. Increased concentration of biologic formulations lead to higher viscosity solutions which are challenging to deliver accurately.
We will find out how to overcome viscosity challenges thanks to syringe options with increased internal needle diameter.
Speakers
Enrico Barichello
Product Manager, Syringe Platform – DCS Glass, Stevanato Group
Alan Xu
Product Manager for Analytical Services, Stevanato Group
Learning Objectives:
- Analytical services can simplify the journey of combination products from early-stage design, all the way through launch
- Specialized PFS syringes meet the key requirements of protein-based or high viscosity drugs
- Auto-injectors which help patient centricity and ease of use are dependent on specialized primary containers
